Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Switch Clear all
Recruiting Not applicable Interventional

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

NCT05230173
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease
Interventions
Pragmatic
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

NCT06515782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 18, 2026, 6:54 AM EDT
Completed No phase listed Observational

Comparison of Dialysis Therapies on Cognitive Function

NCT00597103
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

NCT05814627
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
85
States / cities
Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 18, 2026, 6:54 AM EDT
Enrolling by invitation No phase listed Observational

Precision Medicine in the CICU: Identifying Proteomic Biomarkers

NCT06642662
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Somascan 5.0
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Days to 5 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 18, 2026, 6:54 AM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

NCT06305299
View directory record Official record
Conditions
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
Interventions
iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Narrow Band Imaging Colonoscope

NCT00628147
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
Narrow band imaging colonoscope
Device
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471
View directory record Official record
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 18, 2026, 6:54 AM EDT
Terminated Not applicable Interventional

Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma

NCT06626334
View directory record Official record
Conditions
Rib Fractures, Pain, Acute
Interventions
Bright Blue Light, Bright Full-Spectrum (White) Light, Usual Ambient Light
Device
Lead sponsor
Rebecca E Kotcher, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Not listed Phase 4 Interventional

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

NCT01007630
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
The Parkinson's Institute
Other
Eligibility
Up to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 18, 2026, 6:54 AM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 18, 2026, 6:54 AM EDT
Terminated Not applicable Interventional

A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)

NCT03471702
View directory record Official record
Conditions
Hydrocephalus, Hydrocephalus in Children, Tumor, Brain, Subarachnoid Hemorrhage
Interventions
Smart External Drain - SED
Device
Lead sponsor
Aqueduct Critical Care
Industry
Eligibility
Up to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 18, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional

Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine

NCT07202039
View directory record Official record
Conditions
Tobacco-flavored EC, Sweet-Cooling EC, Sweet Non-cooling EC
Interventions
Brief individual counseling sessions
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mL
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Laryngeal Vibration for Spasmodic Dysphonia

NCT03746509
View directory record Official record
Conditions
Spasmodic Dysphonia
Interventions
Laryngeal Vibration (Treatment), Laryngeal Vibration (Comparator)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 18, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 18, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

NCT06372899
View directory record Official record
Conditions
E-cigarette Use, Cigarette Smoking, Harm Reduction, Tobacco Use
Interventions
E-cigarettes, Oral nicotine pouches
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 18, 2026, 6:54 AM EDT